Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
about
sameAs
The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in ratsRole of central dopamine in pain and analgesiaFurther structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structuresTriple reuptake inhibitors: the next generation of antidepressantsTriple uptake inhibitors: therapeutic potential in depression and beyondCurrent investigational drugs for major depressionEmerging targets for antidepressant therapiesEffects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activitySKF83959 is a novel triple reuptake inhibitor that elicits anti-depressant activityTriple Reuptake Inhibitors: A Premise and PromiseIntracranial self-stimulation to evaluate abuse potential of drugs.Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.Advances in the treatment of depressionInvestigational drugs for treating major depressive disorder.The secrets of a successful clinical trial: compliance, compliance, and compliance.Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in ratsAn improved asymmetric synthetic route to a novel triple uptake inhibitor antidepressant (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol (D-142)Future prospects in depression researchThe novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.Rodent models of treatment-resistant depression.Monoamine transporters: vulnerable and vital doorkeepers.Innovative approaches for the development of antidepressant drugs: current and future strategiesAmitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.Emerging treatments for depression.Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor.Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressantsAmitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?Emerging drugs for major depressive disorder.Substrate and drug binding sites in LeuT.Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.Triple monoamine uptake inhibitors.Triple reuptake inhibitors: a patent review (2006 - 2012).Post-stroke depression and the aging brain.Antidepressant-like activity of adhyperforin, a novel constituent of Hypericum perforatum L.Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract.Synthesis, antidepressant activity, and toxicity of the erythro/threo racemates and optical isomers of 2-(4-benzylpiperazin-1-yl)-1-(5-chloro-6-methoxynaphthalen-2-yl)hexan-1-ol.
P2860
Q21132285-63129E17-94CB-4607-8506-E5DF930F94F3Q22241489-90964E02-29AE-4C78-A2ED-5B88186A6EB3Q24603864-F5C03FE7-B2D3-4EDF-9C4D-C9F59F1B02BAQ24655640-ECA670F7-B970-453F-98DC-92E7BD50F566Q24658248-2DC3DC4F-DB2A-4FBA-BAC5-A72C325C9A12Q28241732-9BD27C76-0D98-47D7-85FB-F3EAB1640D17Q28244223-3BCC39FA-BE2A-411A-8C85-4DF3710DCFCDQ28247614-6C3E1D27-EC13-4F24-B4A7-9860BA6504DBQ28256557-52AB08C7-001F-43F8-826B-D575F222E40FQ28295413-044DAE76-F89C-4B3A-B402-0003200488C4Q28972234-D22FBBC0-BD40-4367-8C55-308B43C176F1Q33845750-66264FDF-C3CB-4E9C-B38E-DCE186F9DC22Q33889048-04A2381B-31EA-43E1-BB64-F6C72DA8B21FQ33999301-2C0776EF-5A2B-4277-B916-8B8861AF853DQ34496251-EB4850B4-6551-4100-B85C-5ACD9FF06897Q34547274-3A0C4AE1-59DC-49D2-AD81-954E3AD6E942Q35030320-FD4F7CFC-8949-4917-8903-6AB407B3CCCAQ35153858-034D16A9-B4F2-42E5-827F-4DF364E902BCQ35209813-324E0EE0-0F88-4268-B491-C7826D99B46DQ35236701-E32F6410-BA9B-432D-9D5C-DA2DFCECA244Q35532003-A5022240-4784-491A-8EC1-F614F0B54577Q35580361-A19C1953-458C-448B-B746-7CB8925DDDDBQ35877150-4DB0395F-41CE-47F5-BCD4-148BDF776F50Q36401400-E05E4E92-CD84-48AB-A451-69FC50530C38Q36511165-BC567578-227F-4810-A269-09CD94C5C80EQ36576250-E99E5332-C3A5-4F82-A98C-39BF6357F092Q36655168-B7DDC7E3-9392-4276-8E49-77E7A3D2AEE3Q36774320-22761983-19C9-4A39-BB09-699B8B8C72D1Q37071538-E4B40C66-2E21-42F5-A90E-D52E74C89219Q37086977-A7AC8032-20F5-44A6-95A6-94878F69FCF6Q37158450-CEF4C30A-EF54-4AF1-978B-89A5557D1FB8Q37564562-A447E5B6-27BD-4DF3-BEC6-C3FDC0D1C211Q37782457-0A311820-D5C4-4C20-B2F4-0CDC376C6F21Q37891098-F9CD9BAC-4C05-4638-91E9-4C2CFCE7A9C2Q38162938-96002E1F-F4DD-4629-962A-8F910F20A987Q38167327-95DACF85-8775-4175-AFD3-80433B9F44E0Q38269517-F6534194-BDF5-41F9-A78A-C214E2C88B66Q42726331-3936B3D2-3742-4CFA-92A3-6DB564F34200Q44371464-7B9A1B66-B4FF-40F0-B081-520CD6925F3BQ44519902-A9CB0FA2-3144-4B08-8691-8F3C7C7C18DB
P2860
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@ast
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@en
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@nl
type
label
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@ast
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@en
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@nl
prefLabel
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@ast
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@en
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@nl
P2093
P3181
P1476
Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor
@en
P2093
Aaron Janowsky
Arnold S Lippa
Bernard Beer
Phil Skolnick
P304
P3181
P356
10.1016/S0014-2999(03)01310-4
P407
P50
P577
2003-02-14T00:00:00Z